Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
bluebird bio (BLUE)
NASDAQ:BLUE
Bluebird Bio (BLUE) Stock Price & Analysis
2,166 Followers
BLUE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.52 - $8.58
Previous Close$2.91
Volume3.61M
Average Volume (3M)4.12M
Market Cap
$311.23M
Enterprise Value$372.79M
Total Cash (Recent Filing)$245.30M
Total Debt (Recent Filing)$306.86M
Price to Earnings (P/E)-2.8
Beta1.27
Next Earnings
Nov 02, 2023EPS Estimate
-$0.68Last Dividend Ex-Date
Nov 05, 2021Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding106,952,739
10 Day Avg. Volume3,282,525
30 Day Avg. Volume4,121,839
Standard Deviation0.19
R-Squared0.08
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)1.03
Price to Sales (P/S)43.46
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue36.55
Enterprise Value/Gross Profit-57.53
Enterprise Value/Ebitda-3.67
Forecast
1Y Price Target
$6.89Price Target Upside140.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Bluebird Bio News
Pre-EarningsBLUE Earnings this Week: How Will it Perform?
Stock Analysis & IdeasBank of America Says These 2 Stocks Could Double Your Money ...
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BLUE FAQ
What was bluebird bio’s price range in the past 12 months?
bluebird bio lowest stock price was $2.52 and its highest was $8.58 in the past 12 months.
What is bluebird bio’s market cap?
Currently, no data Available
When is bluebird bio’s upcoming earnings report date?
bluebird bio’s upcoming earnings report date is Nov 02, 2023 which is in 15 days.
How were bluebird bio’s earnings last quarter?
bluebird bio released its earnings results on Aug 08, 2023. The company reported -$0.67 earnings per share for the quarter, beating the consensus estimate of -$0.705 by $0.035.
Is bluebird bio overvalued?
According to Wall Street analysts bluebird bio’s price is currently Undervalued.
Does bluebird bio pay dividends?
bluebird bio pays a Notavailable dividend of $8.88 which represents an annual dividend yield of N/A. See more information on bluebird bio dividends here
What is bluebird bio’s EPS estimate?
bluebird bio’s EPS estimate is -$0.68.
How many shares outstanding does bluebird bio have?
bluebird bio has 106,952,736 shares outstanding.
What happened to bluebird bio’s price movement after its last earnings report?
bluebird bio reported an EPS of -$0.67 in its last earnings report, beating expectations of -$0.705. Following the earnings report the stock price went up 8.056%.
Which hedge fund is a major shareholder of bluebird bio?
Among the largest hedge funds holding bluebird bio’s share is Baker Bros Advisors LP. It holds bluebird bio’s shares valued at 8M.
---
Bluebird Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.89 (140.07% Upside)
$6.89 (140.07% Upside)
Blogger Sentiment
Bullish
BLUE Sentiment 75%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $63.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.56%
12-Months-Change
Fundamentals
Return on Equity
-40.91%
Trailing 12-Months
Asset Growth
15.66%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
bluebird bio
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
---
Top 5 ETFs holding BLUE
Vanguard Total Stock Market ETF
$10.30M
iShares Core S&P Total U.S. Stock Market ETF
$385.94K
Horizon Kinetics Medical ETF
$99.18K
iShares Russell 3000 ETF
$45.48K
Vanguard Russell 3000 ETF
$18.93K
Up to five ETFs with an Outperform Smart Score that hold BLUE. The ETFs are listed according to market value of BLUE within the ETF
---